In March, two small biotechs partnered to develop a vaccine for COVID-19 using a mechanism called RNA interference (RNAi) – and early data for the drug they ended up developing was positive. So where do things stand now with their vaccine effort, what are the prospects for the future, and which – if either – of the two firms may be a good investment right now? CLICK HERE.
The biotech stock highlighted in today’s article is already up 173% so far this year, and now the author advises that “a historically bullish signal flashing on the charts could indicate even more upside for [the stock] in the coming weeks.” For the stock in question, and how traders looking to speculate on its next move higher may want to go about doing so, CLICK HERE.
The biotech company highlighted in today’s article, specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer, is one that the author has on his list of high-return-potential candidates. Before taking a position in the stock, however, he cautions that investors need to be aware of one issue of concern that could have important consequences for the stock in the short and medium term. For more, CLICK HERE.
“Although the vast majority of biotech stocks are losing money, a handful of these profitable drug developers are valued at levels that make them absolute bargains,” observes the author of today’s article. He proceeds to highlight what he sees as the three biggest bargains in the entire biotech industry right now, including one firm he describes as “the perfect example of a high-growth and profitable biotech stock that’s getting far too little respect on Wall Street.” For more, CLICK HERE.
“Biotech stocks are breaking out,” declares the author of today’s article. When it comes to playing this breakout, however, he advises that the obvious play – which is related to the COVID-19 treatments received by President Trump – may not be the best play, and he illustrates this by sharing his favorite chart from the biotech sector. For more, CLICK HERE.
“Both of these biotechs deserve a lot more attention than they’ve been receiving,” asserts the author of today’s article in regards to two clinical-stage biotech companies that he proceeds to highlight. For these two overlooked and underappreciated biotech stocks – “a member of the IPO class of 2019 that takes a unique approach to the business of drug development” and one with “a relatively strong candidate for the treatment of Parkinson’s disease that’s meant to provide a lifelong benefit with just one shot” – CLICK HERE.
Drugs for pain management, migraines, dry eye disease and Ebola are among those with PDUFA dates – deadlines by which the FDA must review new drug applications – in October. The author of today’s article points out that “PDUFA dates are binary events that invariably serve as make-or-break catalysts for stocks” – and so biotech investors may want to mark these dates on their calendars! For more, CLICK HERE.
Product candidates for the treatment of excessive underarm sweating on one hand, and dry eye disease on the other, could help the two stocks highlighted in today’s article – a clinical-stage biotech company and a clinical-stage pharmaceutical company – surge by more than 100% (and potentially upwards of 500% in the case of one of the stocks), according to analysts at Oppenheimer. For more on these two stocks and their upside potential, CLICK HERE.
What does the most recent data indicate about short interest in the top biotech stocks? The short answer, today’s article notes, is that “short interest in most of these selected biotech stocks increased” compared with the previous report. For the specifics on short interest in each of the top biotech stocks, from Alexion to Vertex, CLICK HERE.
“Call it what you will, but I think traders who’ve dug into the biotech space initially came for the COVID, then figured out there’s far more to this industry than coronavirus treatments,” remarks the author of today’s article. They proceed to examine three biotech penny stocks that, be it due to COVID-related or COVID-unrelated factors, may be worth considering buying – or bypassing. For these three biotech penny stocks – two of which are up by triple digits year-to-date – CLICK HERE.